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Abstract
Background: Networks of trials assessing several treatment options available for the same condition are increasingly
considered. Randomized trial evidence may be missing because of reporting bias. We propose a test for reporting bias
in trial networks.
Methods: We test whether there is an excess of trials with statistically significant results across a network of trials. The
observed number of trials with nominally statistically significant p-values across the network is compared with the
expected number. The performance of the test (type I error rate and power) was assessed using simulation studies
under different scenarios of selective reporting bias. Examples are provided for networks of antidepressant and
antipsychotic trials, where reporting biases have been previously demonstrated by comparing published to Food and
Drug Administration (FDA) data.
Results: In simulations, the test maintained the type I error rate and was moderately powerful after adjustment for
type I error rate, except when the between-trial variance was substantial. In all, a positive test result increased
moderately or markedly the probability of reporting bias being present, while a negative test result was not very
informative. In the two examples, the test gave a signal for an excess of statistically significant results in the network of
published data but not in the network of FDA data.
Conclusion: The test could be useful to document an excess of significant findings in trial networks, providing a
signal for potential publication bias or other selective analysis and outcome reporting biases.
Keywords: Publication bias, Selective outcome reporting, Test of bias, Randomized controlled trials, Comparative
effectiveness research
Background
Reporting bias proceeds from the tendency of researchers,
pharmaceutical companies and journals to publish trial
results based on the direction, magnitude and statistical
significance of the results [1,2]. It is still a major con-
cern for meta-analysts because, if statistically significant
“positive” results are more likely available, a meta-analysis
based on these results will be biased [3]. In particu-
lar, selective analysis and outcome reporting biases are
increasingly being considered as more common and thus
a potentially greater threat than publication bias [4].
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Numerous statistical tests have been introduced to
detect the presence of reporting bias in conventional
meta-analyses [5-11]. Most formally assess the extent of
asymmetry in funnel plots as a sign of small-study effects,
the tendency for smaller trials to show larger treatment
effect estimates, whatever the reasons [12,13]. Instead
of testing whether smaller trials yielded different treat-
ment effect estimates than did larger trials, Ioannidis and
Trikalinos proposed testing for an excess number of trials
with statistically significant results in a meta-analysis [14].
Unlike for other tests, the performance of this test has
not been evaluated by simulation studies under different
scenarios and thus the Cochrane Collaboration has not
yet recommended its use in conventional meta-analyses
[15]. The test is underpowered in cases of only a few tri-
als with significant results in a meta-analysis, which is
a common scenario in single meta-analyses of random-
ized trials. However, the major advantage of the test is
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that it can be used to examine large bodies of evidence
from many meta-analyses, and identify biases that per-
tain to such larger bodies of evidence. This feature sets
it apart from other proposed tests of selective reporting
bias. Thus the test has been used in evaluating bias across
bodies of evidence including dozens to hundreds of meta-
analyses in diverse fields such as genetics, brain volume
abnormalities, and biomarkers [16-20].
The classic situation of many meta-analyses of random-
ized trials with the same setting, disease and outcome
is network meta-analysis [21-23]. The pairwise meta-
analyses that are combined in a network meta-analysis
address different treatment comparisons, but the trials are
considered to be similar (“coherent”) enough for analy-
sis under the same network. Reporting bias can also be
a major, and probably neglected, concern in network of
trials and their meta-analyses [24,25]. Networks of tri-
als and their meta-analyses are increasingly being used
[26]. Although reporting bias may have an important
impact on treatment efficacy estimates, many published
network meta-analyses fail to address formally or discuss
the possibility of publication bias and related small-study
bias [27,28]. Moreover, there is a need to develop reli-
able tests for reporting bias across an entire network of
trials. A test providing statistical signals, provided it is
used soundly, would complement and enhance network
meta-analyses as a systematic effort to summarize evi-
dence stemming from a network of trials. We propose
to apply the Ioannidis-Trikalinos test in networks of tri-
als. Because the test was originally introduced and further
used to explore research domains, it can be readily used
for trial networks [17-19,29,30].
Methods
Test of bias in a conventional meta-analysis
We consider a meta-analysis of n trials. We test whether O,
the observed number of trials with statistically significant
results at a specified α level, differs from E, the expected
number of trials with statistically significant results. We
set α = 0.05, the traditional threshold for inference in
randomized trials.
To estimate the expected number E, we assume a true
effect size θ . The expected probability that trial i will find
a statistically significant “positive” result equals its power
1 − βi to detect θ at the specified α level. The expected
number E equals the sum of the power estimates across all
trials selected in the meta-analysis, E = ∑ni=1 1 − βi.
The true effect size θ for any meta-analysis is not known.
Thus, we must make assumptions about a plausible effect.
Such plausible effects could be: the fixed-effect summary,
the random-effects summary or the treatment effect esti-
mate of the largest trial in the meta-analysis, respectively.
One may also consider not just a point estimate but also a
prior distribution for the plausible effect. However, prior
work has shown that results are very similar to using a
point estimate [14], which is what we use here.
We test whether the observed number O is greater than
the expected number E at a statistical level α′ using a
binomial probability test. We set α′ = 0.10, as is typical
for selective reporting bias tests. Consequently, we would
reject the null hypothesis in favor of excess significant
findings if
∑n
k=O b(k|n, p) < α′, where p = E/n is the
average probability that a specific trial will find a “positive”
result and b(k|n, p) = (nk)pk(1 − p)n−k is the binomial dis-
tribution function. Because the test is based on observed
and expected numbers of “positive” results, it can be used
for binary, continuous or time-to-event outcome data.
For binary outcome data, let us assume that we observe
xEi and xCi events in nEi and nCi patients in the experimen-
tal and control groups of trial i, respectively. We estimate
the true proportion of event in the control group by
π̂Ci = xCi/nCi and the true proportion of events in the






the true odds-ratio between the experimental and control
groups. Then, 1 − βi is estimated as the power of the two-
sided Fisher’s exact test to detect the difference between
π̂Ei and π̂Ci in nEi and nCi patients at the specified α level.
O is the number of trials with significant p-value at a sig-
nificance level α with a two-sided Fisher’s exact test based
on xEi, xCi, nEi, nCi.
For continuous outcome data, let us assume that we
observe the means and standard deviations mEi, sEi and
mCi, sCi from nEi and nCi patients in the experimental
and control groups, respectively, of trial i. The true mean
in the control group is estimated by μ̂Ci = mCi and
the true mean in the experimental group is estimated by
μ̂Ei = μ̂Ci + sig, with g the true standardized mean dif-







deviation, pooled across groups. Then, 1 − βi is estimated
as the power of the two-sided t-test to detect a difference
between μEi and μCi in nEi and nCi patients at the spec-
ified α level. O is the number of trials with significant
p-value at a significance level of α with a two-sided t-test
based on mEi, sEi, nEi and mCi, sCi, nCi.
Test of bias in a network of trials
We consider that the network of trials can be described as
J meta-analyses of nj trials each. We estimate the expected
number Ej of trials with statistically significant results for
each meta-analysis across the network by assuming a true
effect size θj for each meta-analysis. The expected num-
ber E is estimated as E = ∑Jj=1 Ej = ∑Jj=1 ∑nji=1 1 − βi.
Estimation of the true effect size for each meta-analysis
is based on a plausible effect size, as above. The observed
number O = ∑Jj=1 Oj is the total number of trials with
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significant p-values across the network. We test whether
the observed number O is greater than the expected
number E using a one-tail binomial probability test. Let
N = ∑Jj=1 nj. We would reject the null hypothesis in favor
of excess significant findings if
∑N
k=O b(k|N , P) < α′,
where P = E/N is the average probability that a specific
trial across the network will find a “positive” result.
Detection of excess significant findings does not mean
that all pairwise meta-analyses included in the network
have been equally affected by the same bias. Even if the
bias is exchangeable across all pairwise meta-analyses in
the network, we may observe that some pairwise meta-
analyses are affected more than others, and some are not
affected at all. For instance, for 3 meta-analyses with 10
trials per meta-analysis, and because of reporting bias,
10% of the evidence disappears in a “file drawer”, it is
within the range of chance that these 3 file-drawer tri-
als may come one from each meta-analysis, or all 3 may
come from the same meta-analysis. However, detection of
excess significance suggests that selective reporting bias
may have affected the results of this whole body of evi-
dence and thus inferences should be cautioned in this
regard.
Simulation studies
We assessed the type I error rate and power of the test
using Monte Carlo simulation studies. These simulations
were based on binary outcome data. The protocol for sim-
ulation studies is described in detail in the Additional
file 1.
For a given meta-analysis (i.e., a given pair of experimen-
tal and control treatments), we set the number of trials n,
the true average treatment effect as θ and the between-
trial variance τ 2 and we generated the number of events
and non-events in the experimental and control groups
for each trial under a random-effects model. We used n as
(6, 10, 30); θ as (0.5, 0.75, 1.0); τ 2 as (0.02, 0.08, 0.25).
To simulate reporting bias affecting trials in a given
meta-analysis, we considered a selection model that
links the probability of trial selection to both trial size
and intensity of treatment effect [9,31,32]. A correlation
parameter ρ defines the extent of reporting bias. When
we induced reporting bias, we simulated data until n trials
had been selected. As sensitivity analysis, we also consider
a model that selects trials depending on the p-value for
treatment effect associated with the trial [5-7].
We simulated a network of trials as J meta-analyses
of nj = n trials each. For each meta-analysis j, we set
the true average treatment effect θj. We considered 4
distinct scenarios by setting known relative effects from
log(θj) ∼ N (ψ , ν) with ψ equal to ψ1 = log(0.75) or
ψ2 = log(0.95) and ν equal to ν1 = 0.02 or ν2 = 0.08.
The sets of realizations are reported in Table 1. We further
assumed homogeneity of between-trial variation within
the J meta-analyses, i.e., τ 2j = τ 2. We took J as (6, 10),
n as (3, 6), θj as in Table 1, and τ 2 as (0.02, 0.08, 0.25).
These values were based on the characteristics of a large
sample of Cochrane meta-analyses [33,34]. For a given
meta-analysis, data were then generated as described.
Reporting bias was induced for each of the J meta-
analyses constituting the network as described, under the
assumption that the propensity for bias would be similar
across the J meta-analyses. When selecting trials accord-
ing to trial size and treatment effect magnitude, we drew
each ρj from an uniform distribution over the support
[ρmin; ρmax]. We considered ρj ∼ U [−0.8; −0.6] or ρj ∼
U [−1.0; −0.8] to reflect similar moderate and severe bias,
respectively, across the J meta-analyses.
For each scenario, we generated 10,000 datasets. We
assessed the empirical type I error rate and power for sce-
narios without and with reporting bias, respectively. We
took into account the possibly differing type I error rates
of the tests and we estimated powers adjusted for type
I error rate [35]. Moreover, we estimated the likelihood
ratio of a positive test result (ie, the likelihood that a signif-
icant test result is found in networks with bias as opposed
to networks without bias) and the likelihood ratio of a
negative test result (ie, likelihood that a non-significant
Table 1 True average treatment effects θj used to generate networks of trials
Treatment Dispersion of No. of True average treatment effects
effect ψ treatment effect ν meta-analyses J θj , j = 1, · · · , J
ψ1 = log(0.75) ν1 = 0.02 6 0.793, 0.889, 0.741, 0.954, 0.569, 0.684
ψ1 = log(0.75) ν2 = 0.08 6 0.808, 0.725, 0.876, 0.698, 0.699, 0.395
ψ2 = log(0.95) ν1 = 0.02 6 0.796, 1.172, 1.000, 1.171, 1.099, 0.883
ψ2 = log(0.95) ν2 = 0.08 6 0.491, 1.214, 0.936, 0.977, 1.451, 0.754
ψ1 = log(0.75) ν1 = 0.02 10 0.658, 0.852, 0.696, 0.889, 0.741, 0.722, 0.645, 0.683, 0.816, 0.796
ψ1 = log(0.75) ν2 = 0.08 10 0.978, 0.432, 1.149, 0.706, 0.432, 0.751, 0.679, 0.653, 0.624, 0.568
ψ2 = log(0.95) ν1 = 0.02 10 1.081, 1.089, 0.767, 0.973, 0.781, 0.763, 1.266, 0.816, 1.066, 0.992
ψ2 = log(0.95) ν2 = 0.08 10 0.845, 0.637, 1.030, 0.799, 0.541, 0.851, 1.063, 1.307, 0.674, 0.732
We set the relative effects θj , j = 1, . . . , J from log(θj) ∼ N (ψ , ν).
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test result is found in networks with bias as opposed to
networks without bias) [36]. Analyses involved use of R
v2.12.2 (R Development Core Team, Vienna, Austria).
In the cases of a conventional meta-analysis, we also
assessed for comparison purposes the performance of the
test introduced by Rücker et al. based on a weighted
regression of the arcsine transformation of observed risks
with explicit modeling of between-trial heterogeneity [9].
Application of the test with 2 trial networks
We provide two illustrations of the test for networks of
antidepressant and antipsychotic trials where strong and
weak selective reporting biases have been convincingly
demonstrated based on a comparison of FDA data versus
published data (Figure 1).
Networks of antidepressant trials
For the antidepressant trials, we used 2 star-shaped net-
works created from US Food and Drug Administration
(FDA) reviews of antidepressant trials and their match-
ing publications [37]. Turner et al. originally identified
all randomized placebo-controlled trials of 12 antidepres-
sant drugs approved by the FDA and then all publications
matching these trials. The authors identified 74 trials reg-
istered with the FDA but only 51 trials had published
results. They showed that the 23 entire trials remained
with unpublished results because of the negative nature
of the results. Moreover, in some journal articles, specific
analyses were reported selectively and effect sizes differed
from that in FDA reviews. The outcome was the change
from baseline to follow-up in depression severity score.
The measure of effect was a standardized mean difference.
To illustrate the test, we used the effect sizes reported by
Turner et al. (table C in the Supplementary Appendix from
[37]). Because the results of 2 paroxetine CR (controlled
release) trials with published results were combined, it
made a total of 73 trials registered to the FDA and 50 trials
with published results for our assessment.
Figure 1 Networks of antidepressant and antipsychotic trials.
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Networks of antipsychotic trials
Turner et al. also used FDA data to assess whether the
apparent efficacy of second-generation antipsychotics had
been influenced by reporting bias [38]. The authors iden-
tified the phase 2/3 randomized placebo-controlled trials
of 8 antipsychotic drugs approved by the FDA and then
all publications matching these trials. The authors iden-
tified 24 trials registered with the FDA, among which 20
had published results. The outcome was the change from
baseline to follow-up in schizophrenia symptom ratings.
The measure of effect was a standardized mean differ-
ence. We used the effect sizes reported by Turner et al.
(Tables S2 and S3 in Supplementary Appendix from [38]).
Because the results of one risperidone trial was published
as two separate trials, it made a total of 25 trials registered
to the FDA and 21 trials with published results for our
assessment.
Results
Simulation studies in a conventional meta-analysis
Complete results in the cases of a conventional meta-
analysis are reported in the Additional file 2. Briefly, the
proposed test showed type I error inflation when hetero-
geneity was substantial (between-trial variance of 0.25)
and/or with a large number of trials per meta-analysis
(30 trials). On the contrary, the arcsine test introduced by
Rücker et al. maintained a better type I error rate across
all scenarios. With low number of trials per meta-analysis,
all tests had low power. When the true odds ratio was
0.5, the heterogeneity low or moderate and the number
of trials large, the proposed test, with the true effect size
estimated as the fixed-effect or random-effects summary,
had acceptable power. In all other cases, because of the
inflation of the type I error rate, the power adjusted for
type I error rate of the proposed test was clearly insuffi-
cient. When selection of trials was modeled by trial size
and intensity of treatment, the most powerful test was the
arcsine test.
Simulation studies in a network of trials
Type I error rate
Results for scenarios without reporting bias are presented
in Figure 2. The empirical type I error rate increased with
increasing heterogeneity and increasing numbers of meta-
analyses and trials per meta-analysis. Whatever the vector
of true average treatment effects, the proposed test was
too conservative with low between-trial variance within a
meta-analysis (τ 2 = 0.02). Conversely, error inflation was
substantial with substantial between-trial variance within
a meta-analysis (τ 2 = 0.25) except when the true effect
Figure 2 Type I error rate of the extended tests for reporting bias in a network of trials.
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size was estimated as the treatment effect estimate of the
largest trial in the meta-analysis with the empirical type I
error rate being in good agreement with the pre-specified
significance level of 0.10.
Power
Results for scenarios with reporting bias are presented in
Figure 3 (each ρj ∼ U [−1.0; −0.8]). Across all scenarios,
visual inspection of the trellis graphs showed that the
power adjusted for type I error rate increased with
increasing number of meta-analyses and trials per meta-
analysis and with decreased between-trial variance within
a meta-analysis. With 6 meta-analyses and 3 trials per
meta-analysis, all tests had low to moderate power. When
selection of trials was modeled by trial size and treat-
ment effect magnitude, the power adjusted for type I error
rate increased when the true average odds ratios moved
away from 1. The proposed test with the true effect size
estimated as the treatment effect estimate of the largest
trial in the meta-analysis showed greater adjusted power
than with the fixed-effect summary and the latter showed
greater adjusted power than with the random-effects
summary. Results for other extents of bias were similar
(Additional file 3). When selection of trials was modeled
by p-value, the adjusted power was still the smallest when
the true effect size was estimated as the random-effects
summary, while fixed effects and largest trial effect sizes
had relatively similar performance (Additional file 3).
We also ran simulations with another set of vectors
of true average treatment effects θj. Results were similar
(not shown).
Likelihood ratio
Likelihood ratios of a positive test result indicated that
the proposed test had modest (with substantial hetero-
geneity) or high (with little or no heterogeneity) effect on
increasing the likelihood of bias. Likelihood ratios of a
negative test result indicated that the proposed test had
a weak to moderate effect in decreasing the likelihood of
bias (Figure 4). The proposed test with the true effect size
estimated as the estimate of the largest trial yielded the
best likelihood ratios. The performance of the test was
poor with the true effect estimated as the random-effects
summary.
Application of the test with 2 trial networks
Networks of antidepressant trials
When we considered the fixed-effect summaries as the
plausible effect sizes, the observed number of trials with
significant results across the network of published data
Figure 3 Adjusted power of the extended tests for reporting bias in a network of trials.
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Figure 4 Likelihood ratios of the extended tests for reporting bias in network of trials.
was larger than the expected number (Table 2). This
excess was statistically significant at the pre-specified level
of 0.10 (binomial probability test p = 0.05) which may
indicate bias in trials with published results. However,
across the network of FDA data, we found no signal of an
excess of statistically significant results (p = 0.24). Results
were similar when using random-effects summaries as
plausible effect sizes. However, when using the estimates
of the largest trials as plausible effect sizes, there was still
an even stronger signal for an excess of statistically signif-
icant results in the published data and there was a signal
even in the network of FDA data. The latter signal is not
necessarily a false-positive: even though the FDA data are
more complete and unbiased than the published data, it is
possible that some bias may have existed even in the FDA
data [39].
Table 2 Application of the test with networks of antidepressant and antipsychotic trials
Antidepressant trials
Published data FDA data
(N=51 trials) (N=74 trials)
Plausible effects O E p O E p
Fixed-effect summary 41 35.3 0.05 38 34.5 0.24
Random-effects summary 41 35.6 0.06 38 34.6 0.25
Largest trial 41 31.3 0.002 38 29.0 0.02
Antipsychotic trials
Published data FDA data
(N=20 trials) (N=24 trials)
Plausible effects O E p O E p
Fixed-effect summary 19 18.1 0.43 20 19.6 0.53
Random-effects summary 19 18.4 0.50 20 34.6 0.56
Largest trial 19 16.1 0.10 20 18.6 0.36
O and E are the observed and expected total numbers of trials with statistically significant results across the network; p is the p-value associated with a one-tail
binomial probability test to asssess if O is greater than the E.
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Networks of antipsychotic trials
When we considered the fixed-effect summaries as the
plausible effect sizes, we found no evidence of an excess of
statistically significant results across the network of pub-
lished data and the network of FDA data. Results were
similar when using random-effects summaries as plausi-
ble effect sizes. However, when using the estimates of the
largest trials as plausible effect sizes, there was a signal for
an excess of statistically significant results in the network
of published data but not in the network of FDA data.
Discussion
In this paper, we proposed a test for reporting bias in
networks of trials. The test is based on the observed
and expected numbers of trials with statistically signif-
icant results across the network. In simulation studies,
we found that the type I error rate of the proposed test
was in agreement with the nominal type I error level and
that the proposed test had overall moderate power after
adjustment for type I error rate, except when the between-
trial variance was substantial in which case the empirical
type I error rate was considerably inflated and the empir-
ical power was low. In all, a positive test result increases
modestly or even markedly the probability of reporting
bias being present, while a negative test result is not very
informative.
The proposed test fits well with the widespread notion
that a treatment effect estimate has to pass a cut-off of sta-
tistical significance, resulting in an aversion to null results
or, conversely, in significance chasing [40,41]. Although
the test does not make any assumption about small-study
effects, publication bias and related types of small-study
effects may explain the excess significance, with bias being
more pronounced in smaller trials. For instance, in an
empirical assessment of animal studies of neurological
diseases, the strongest excesses of significance were found
in meta-analyses where small-study effects were found
[42]. Finally, an excess of significant results could reflect
suppression of results of entire trials but also selective
analysis and outcome reporting practices, or even fabri-
cation of positive results (although this latter scenario is
likely more rare for clinical trials) [43]. In fact, reporting
bias encompasses several mechanisms that may act solely
or simultaneously, but all may be motivated by statistical
significance.
In a network of trials, conventional tests for asymme-
try could be applied to each meta-analysis constituting
the network. If reporting bias is detected in any pairwise
comparison, meta-analysts have a signal that they should
interpret the synthesis results with caution. However,
the number of trials addressing each pairwise compari-
son may often be limited (< 10 trials for each pairwise
comparison), which would prevent this approach from
documenting or excluding reporting bias appropriately
[30-32]. Moreover, testing one-at-a-time the multiple
meta-analyses comprising the network may result in some
false-positive asymmetry test result simply by chance.
Here, the proposed test involves a single evaluation of the
entire network, thus avoiding this multiplicity. Moreover,
it borrows strength from trials across the network under
the assumption that biases are exchangeable, that is biases,
if present, operate in a similar way in trials across the net-
work. As discussed elsewhere, if we have no information
to distinguish different reporting bias mechanisms across
the network, bias exchangeability is plausible and it still
allows that eventually some meta-analyses will be affected
by bias more than others within the range afforded by
chance [44].
Decisions about conclusiveness and dissemination of
research findings are commonly based on statistical sig-
nificance (only) and this practice is likely to affect any
network of evidence. We acknowledge that the exchange-
ability assumption may not be tenable in contexts in which
reporting biases may affect the network in a systemati-
cally unbalanced way. For instance, only some pairwise
comparisons could be affected and not others. However,
the proposed test could still be useful in such networks if
there are sufficient numbers of trials across the affected
pairwise comparisons.
To estimate the expected number of trials with statis-
tically significant results, estimates of the unknown true
effect sizes for each meta-analysis in the network are
required. In this regard, the true effect sizes are approxi-
mated by pooled estimates using just the very trials that
are suspected to be affected by a meta-bias. However, we
note that, in the presence of reporting bias, the fixed-
effect or random-effects summary effects are likely to be
biased and overestimate the true effect. Even the effect
size from the largest trial in the meta-analysis may be
biased sometimes, and often there may be no large enough
trial. Consequently, the plausible effects used are conser-
vative in testing for excess statistical significance. More-
over, because a random-effects meta-analysis gives larger
relative weights to smaller trials than does a fixed-effect
meta-analysis, the random-effects summary may be the
farthest from the true effect in the presence of reporting
bias. This may explain why the power of the proposed test
was poorer when using the random-effects summaries as
plausible effects. Finally, we explored the use of the single
most precise trials and found that the proposed test had
fair power. Therefore, for applications at the network level,
we propose using either the result of the largest (most pre-
cise) trial or the fixed-effect summary. The former choice
may often have a minor advantage.
The proposed test relied on further assumptions. We
assumed that the observed number of trials with signifi-
cant findings could be modelled by a common binomial
parameter. However, because trial size varies within each
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meta-analysis, because the numbers of trials and the num-
bers of trials with significant findings vary across the
meta-analyses constituting the network, the distribution
of the total number of trials with significant findings
is more complex. Moreover, we estimated the plausible
effects based only on direct evidence and by considering
that different comparisons in the network were inde-
pendent. Other options may be considered for plausible
effects. First, estimates from a consistency network meta-
analysis model may be used as plausible effects. In the
examples of antidepressant and antipsychotic trials, there
were no closed loops, so this would not be relevant.
But in cases where there are closed loops and network
meta-analysis estimates can be obtained, it would be use-
ful to compare the results of the excess significance test
using also the network meta-analysis estimates as plausi-
ble effects in a sensitivity analysis. However, differential
reporting bias may lead to violation of the consistency
assumption [23]. The biases may operate in different
directions across the meta-analyses constituting the net-
work and biases could theoretically be cancelled out or
exacerbated when indirect comparisons are made. More-
over, a single meaningful network meta-analysis is not
feasible for many networks of trials (without any closed
loop or in cases of disconnected sets of trial comparisons).
Second, our simulation studies based on the Copas model
showed that the arcsine transformation could outperform
other options in a conventional meta-analysis [9]. But this
metric, which concern dichotomous outcomes only, is not
widely used in the literature yet and it cannot be used to
combine results in network meta-analysis. However, by
extension it is possible to apply the arcsine transforma-
tion to all the pairwise meta-analyses of a network for the
purpose of excess significance testing. This approach may
improve the method to maintain type 1 error rates.
A potential concern with the proposed test is that
reporting bias and between-trial heterogeneity may be
confounded. In fact, the type I error rate was inflated with
increased between-trial variance. This is a typical issue
with all tests of reporting bias introduced for conven-
tional meta-analysis. However, we observed this finding
with between-trial variance equal to 0.25 (only 25% of
meta-analyses have this extent of heterogeneity [34]) and
when assuming that all meta-analyses constituting the
network had this amount of between-trial heterogeneity,
which may be infrequent in practice. In such cases, all the
evidence should perhaps be reconsidered before synthe-
sis; that is, sources of heterogeneity should be explored
and the test may still be applied considering a subset of
more homogeneous trials. As well, it should be noted that
reporting bias practices per se may induce between-trial
heterogeneity [45,46]. Regardless, the test should be used
and interpreted wisely. In cases of a statistically signifi-
cant signal of bias, one should not conclude that this bias
is specifically publication bias, since it could reflect other
practices such as selective analysis and outcome report-
ing biases. In the absence of significant signals of bias,
one should not exclude the possibility of reporting bias,
because a âĂIJnegativeâĂİ test result typically does not
greatly decrease the prior odds of bias, unless in cases
of many trials or substantial between-trial heterogeneity
[47].
Although we illustrated the test with star-shaped net-
works of trials, the test can be used for networks of trials
with closed loops. In this regard, a particular strength of
our simulation studies is that the sets of realizations could
reflect networks of placebo-controlled trials, head-to-
head trials or both placebo-controlled and head-to-head
trials. Moreover, multi-arm trials are frequent in networks
of trials. The proposed test may handle them if a K-arm
trial is analysed as K(K−1)/2 independent two-arm trials,
with variances adjusted to compensate for the correlation
between the corresponding estimates [48].
Our simulation studies have several limitations. First,
values of variables were derived from a large sample
of Cochrane meta-analyses to have realistic scenarios
[33,34]. However, we cannot exclude that some meta-
analyses in this sample were affected by reporting biases.
Reporting bias may have influenced the observed num-
bers of trials, trial sample sizes and between-trial hetero-
geneity [46]. Second, we found that the type I error and
power of the proposed test varied depending on char-
acteristics of the network known to the meta-analysts
and other characteristics which will be always unknown,
such as the nature of the trial selection mechanism. We
addressed this issue by generating data under two previ-
ously used selection models: by trial size and intensity of
treatment effect [9,31,32] or by p-value for the treatment
effect associated with the trial [5,7] and we found simi-
lar results. Of note, the proposed test does not directly
make assumptions about small-study effects, whereas the
Copas model assumes that trial selection depends upon
trial size. We used this approach to estimate the operating
characteristics of the test through a data generation pro-
cess based on a plausible and realistic model for reporting
bias but that did not fit exactly the principle underlying
the test, i.e., significance chasing. Third, we considered
true event rates between 0.3 and 0.7. The test may lose
power when event rates are lower (or, equivalently, very
high), but no test can have very good performance under
such conditions. If a few meta-analyses in a network have
event rates in the 0.3-0.7 range, these would be the ones
primarily contributing to the power of the test. Fourth, we
used a normal approximation to the likelihood, instead of
the exact binomial likelihood, in the modeling for meta-
analysis. This approximation is less precise for probabili-
ties of events close to 0 or 1. Lastly, we did not consider
the network geometry for our simulation. Instead, the
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simulation relied on some hyperdistribution of the true
effect sizes for all comparisons.
Some other modeling approaches have been introduced
recently to investigate the extent of reporting bias in a net-
work meta-analysis. Mavridis et al. presented a Bayesian
implementation of the Copas selection model extended
to network meta-analyses [49]. The correlation parame-
ter ρ is assumed equal for all comparisons and indicates
the extent of reporting bias. Moreover, network meta-
regression models that allows the treatment effect size
to depend on its standard error or variance have been
described [44,50]. Under an assumption of exchangeable
bias, a posterior mean slope is estimated and indicates
the extent of small-study effect across the network. Other
types of biases in a network, such as novelty bias, can
be modeled with meta-regressions [51]. Some biases may
affect not only a single network, but may be exchange-
able across multiple networks (eg, all networks of systemic
treatments for diverse types of cancer may suffer from
similar biases, since more or less the same drugs and
regimens are used for different cancers [51]). In these
cases, one could apply the excess significance test across
a collection of several such networks with exchangeable
biases.
Conclusion
The proposed excess significance test could be useful to
provide a statistical signal indicating an excess of signifi-
cant findings in clinical trial networks. If such a signal is
detected across the network of trials or in specific pairwise
comparisons by conventional approaches, the network of
trials and its meta-analyses should be considered with
caution.
Additional files
Additional file 1: Protocol of simulation studies.
Additional file 2: Results of simulation studies for conventional
meta-analysis.
Additional file 3: Additional results of simulation studies for trial
networks.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
LT, JPAI, GC and PR drafted the manuscript, and read and approved the final
manuscript.
Acknowledgements
The authors thank Laura Smales (BioMedEditing, Toronto, Canada) for
copy-editing the manuscript.
Financial disclosure
Grant support was from the European Union Seventh Framework Programme
(FP7 – HEALTH.2011.4.1-2) under grant agreement n 285453 (http://www.
open-project.eu). Our team is supported by an academic grant
(DEQ20101221475) for the programme “Equipe espoir de la Recherche” from
the Fondation pour la Recherche Médicale. The funders had no role in study
design, data collection and analysis, decision to publish, or preparation of the
manuscript.
Author details
1INSERM U1153, Hôpital Hôtel-Dieu, 1 place du Parvis Notre-Dame, 75004
Paris, France. 2Centre Cochrane Français, Paris, France. 3Department of
Epidemiology, Columbia University Mailman School of Public Health, New
York, NY, USA. 4Stanford Prevention Research Center, Department of Medicine
and Department of Health Research and Policy, Stanford University School of
Medicine, Stanford, CA, USA. 5Department of Statistics, Stanford University
School of Humanities and Sciences, Stanford, CA, USA. 6Meta-Research
Innovation Center at Stanford (METRICS), Stanford University, Stanford, CA,
USA. 7Université Paris Descartes - Sorbonne Paris Cité, Paris, France. 8INSERM
CIE 4, Paris, France. 9Assistance Publique-Hôpitaux de Paris, Hôpital Européen
Georges Pompidou, Unité de Recherche Clinique, Paris, France. 10Assistance
Publique-Hôpitaux de Paris, Hôpital Hôtel-Dieu, Centre d’Epidémiologie
Clinique, Paris, France.
Received: 2 April 2014 Accepted: 18 September 2014
Published: 27 September 2014
References
1. McGauran N, Wieseler B, Kreis J, Schuler Y, Kolsch H, Kaiser T: Reporting
bias in medical research - a narrative review. Trials 2010, 11:37.
2. Song F, Parekh S, Hooper L, Loke Y, Ryder J, Sutton A, Hing C, Kwok C,
Pang C, Harvey I: Dissemination and publication of research findings:
an updated review of related biases. Health Technol Assess 2010,
14:1–193.
3. Hopewell S, Loudon K, Clarke M, Oxman A, Dickersin K: Publication bias
in clinical trials due to statistical significance or direction of trial
results. Cochrane Database Syst Rev 2009, 1:MR000006.
doi:10.1002/14651858.MR000006.pub3.
4. Dwan K, Altman D, Arnaiz J, Bloom J, Chan A, Cronin E, Decullier E,
Easterbrook P, Von Elm E, Gamble C, Ghersi D, Ioannidis J, Simes J,
Williamson P: Systematic review of the empirical evidence of study
publication bias and outcome reporting bias. PLoS One 2008, 3:3081.
5. Begg C, Mazumdar M: Operating characteristics of a rank correlation
test for publication bias. Biometrics 1994, 50:1088–101.
6. Harbord R, Egger M, Sterne J: A modified test for small-study effects in
meta-analyses of controlled trials with binary endpoints. Stat Med
2006, 25:3443–57.
7. Macaskill P, Walter S, Irwig L: A comparison of methods to detect
publication bias in meta-analysis. Stat Med 2001, 20:641–54.
8. Rücker G, Carpenter J, Schwarzer G: Detecting and adjusting for
small-study effects in meta-analysis. Biom J 2011, 53:351–68.
9. Rücker G, Schwarzer G, Carpenter J: Arcsine test for publication bias in
meta-analyses with binary outcomes. Stat Med 2008, 27:746–63.
10. Schwarzer G, Antes G, Schumacher M: Inflation of type i error rate in
two statistical tests for the detection of publication bias in
meta-analyses with binary outcomes. Stat Med 2002, 21:2465–77.
11. Schwarzer G, Antes G, Schumacher M: A test for publication bias in
meta-analysis with sparse binary data. Stat Med 2007, 26:721–33.
12. Sterne J, Sutton A, Ioannidis J, Terrin N, Jones D, Lau J, Carpenter J,
Rücker G, Harbord R, Schmid C, Tetzlaff J, Deeks J, Peters J, Macaskill P,
Schwarzer G, Duval S, Altman D, Moher D, Higgins J: Recommendations
for examining and interpreting funnel plot asymmetry in
meta-analyses of randomised controlled trials. BMJ 2011, 343:4002.
13. Ioannidis J, Trikalinos T: The appropriateness of asymmetry tests for
publication bias in meta-analyses: a large survey. CMAJ 2007,
176(8):1091–1096.
14. Ioannidis J, Trikalinos T: An exploratory test for an excess of significant
findings. Clin Trials 2007, 4:245–53.
15. Sterne J, Egger M, Moher D: Chapter 10: Addressing reporting biases.
In Cochrane Handbook for Systematic Reviews of Interventions. Edited by
Higgins JSG. Chichester, UK: The Cochrane Collaboration and John Wiley
and Sons Ltd; 2011:297–333.
16. Chatzinasiou F, Lill C, Kypreou K, Stefanaki I, Nicolaou V, Spyrou G,
Evangelou E, Roehr J, Kodela E, Katsambas A, Tsao H, Ioannidis J,
Bertram L, Stratigos A: Comprehensive field synopsis and systematic
Trinquart et al. BMC Medical Research Methodology 2014, 14:112 Page 11 of 11
http://www.biomedcentral.com/1471-2288/14/112
meta-analyses of genetic association studies in cutaneous
melanoma. J Natl Cancer Inst 2011, 103:1227–35.
17. Ioannidis J: Excess significance bias in the literature on brain volume
abnormalities. Arch Gen Psychiatry 2011, 68:773–80.
18. Kavvoura F, McQueen M, Khoury M, Tanzi R, Bertram L, Ioannidis J:
Evaluation of the potential excess of statistically significant findings
in published genetic association studies: application to alzheimer’s
disease. Am J Epidemiol 2008, 168:855–65.
19. Tsilidis K, Papatheodorou S, Evangelou E, Ioannidis J: Evaluation of
excess statistical significance in meta-analyses of 98 biomarker
associations with cancer risk. J Natl Cancer Inst 2012, 104:1867–78.
20. Tzoulaki I, Siontis K, Evangelou E, Ioannidis J: Bias in associations of
emerging biomarkers with cardiovascular disease. JAMA Internal Med
2013, 173:664–71.
21. Ioannidis J: Integration of evidence from multiple meta-analyses:
a primer on umbrella reviews, treatment networks and multiple
treatments meta-analyses. CMAJ 2009, 181:488–93.
22. Salanti G, Ades A, Ioannidis J: Graphical methods and numerical
summaries for presenting results from multiple-treatment
meta-analysis: an overview and tutorial. J Clin Epidemiol 2011,
64:163–71.
23. Salanti G, Higgins J, Ades A, Ioannidis J: Evaluation of networks of
randomized trials. Stat Methods Med Res 2008, 17:279–301.
24. Li T, Puhan M, Vedula S, Singh S, Dickersin K: Network
meta-analysis-highly attractive but more methodological research
is needed. BMC Med 2011, 9:79.
25. Mills E, Ioannidis J, Thorlund K, Schunemann H, Puhan M, Guyatt G:
How to use an article reporting a multiple treatment comparison
meta-analysis. JAMA 2012, 308:1246–53.
26. Lee A: Review of mixed treatment comparisons in published
systematic reviews shows marked increase since 2009. J Clin
Epidemiol 2014, 67:138–43.
27. Trinquart L, Abbe A, Ravaud P: Impact of reporting bias in network
meta-analysis of antidepressant placebo-controlled trials. PLoS One
2012, 7:35219.
28. Bafeta A, Trinquart L, Seror R, Ravaud P: Analysis of the systematic
reviews process in reports of network meta-analyses:
methodological systematic review. BMJ 2013, 347:3675.
29. Ntzani E, Rizos E, Ioannidis J: Genetic effects versus bias for candidate
polymorphisms in myocardial infarction: case study and overview
of large-scale evidence. Am J Epidemiol 2007, 165:973–84.
30. Pan Z, Trikalinos T, Kavvoura F, Lau J, Ioannidis J: Local literature bias in
genetic epidemiology: an empirical evaluation of the chinese
literature. PLoS Med 2005, 2:334.
31. Copas J, Shi J: Meta-analysis, funnel plots and sensitivity analysis.
Biostatistics 2000, 1:247–62.
32. Copas J, Shi J: A sensitivity analysis for publication bias in systematic
reviews. Stat Methods Med Res 2001, 10:251–65.
33. Davey J, Turner R, Clarke M, Higgins J: Characteristics of meta-analyses
and their component studies in the cochrane database of
systematic reviews: a cross-sectional, descriptive analysis. BMC Med
Res Methodol 2011, 11:160.
34. Turner R, Davey J, Clarke M, Thompson S, Higgins J: Predicting the
extent of heterogeneity in meta-analysis, using empirical data from
the cochrane database of systematic reviews. Int J Epidemiol 2012,
41(3):818–827.
35. Lloyd C: Estimating test power adjusted for size. J Stat Comput Simulat
2005, 75:921–33.
36. Ioannidis J: Clarifications on the application and interpretation of the
test for excess significance and its extensions. J Math Psychol 2013,
57:184–87.
37. Turner E, Matthews A, Linardatos E, Tell R, Rosenthal R: Selective
publication of antidepressant trials and its influence on apparent
efficacy. N Engl J Med 2008, 358:252–60.
38. Turner E, Knoepflmacher D, Shapley L: Publication bias in antipsychotic
trials: an analysis of efficacy comparing the published literature to
the us food and drug administration database. PLoS Med 2012,
9:1001189.
39. Ioannidis J: Effectiveness of antidepressants: an evidence myth
constructed from a thousand randomized trials? Philos Ethics Humanit
Med 2008, 3:14.
40. Fanelli D: Negative results are disappearing from most disciplines
and countries. Scientometrics 2012, 90:891–904.
41. Ioannidis J: Why most published research findings are false. PLoS Med
2005, 2:124.
42. Tsilidis K, Panagiotou O, Sena E, Aretouli E, Evangelou E, Howells D,
Salman R, MacLeod M, Ioannidis J: Evaluation of excess significance
bias in animal studies of neurological diseases. PLoS Biol 2013,
11(7):1001609.
43. Fanelli D: How many scientists fabricate and falsify research?
a systematic review and meta-analysis of survey data. PLoS One
2009, 4:5738.
44. Trinquart L, Chatellier G, Ravaud P: Adjustment for reporting bias in
network meta-analysis of antidepressant trials. BMC Med Res
Methodol 2012, 12:150.
45. Ioannidis J, Trikalinos T: Authors’ response to v johnson and y yuan.
Clinical Trials 2007, 4:256–7.
46. Jackson D: Assessing the implications of publication bias for two
popular estimates of between-study variance in meta-analysis.
Biometrics 2007, 63:187–93.
47. Ioannidis J: Interpretation of tests of heterogeneity and bias in
meta-analysis. J Eval Clin Pract 2008, 14:951–7.
48. Rücker G: Network meta-analysis, electrical networks and graph
theory. Res Synthesis Methods 2012, 3:312–24.
49. Mavridis D, Sutton A, Cipriani A, Salanti G: A fully bayesian application
of the copas selection model for publication bias extended to
network meta-analysis. Stat Med 2013, 32:51–66.
50. Chaimani A, Salanti G: Using network meta-analysis to evaluate the
existence of small-study effects in a network of interventions.
Res Synthesis Methods 2012, 3:161–76.
51. Salanti G, Dias S, Welton N, Ades A, Golfinopoulos V, Kyrgiou M, Mauri D,
Ioannidis J: Evaluating novel agent effects in multiple-treatments
meta-regression. Stat Med 2010, 29:2369–83.
doi:10.1186/1471-2288-14-112
Cite this article as: Trinquart et al.: A test for reporting bias in trial
networks: simulation and case studies. BMC Medical Research Methodology
2014 14:112.
Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color figure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
